THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Life Sciences: Biotech

Will Alnylam be the next target for a big tech buyout?

Cambridge drug firm's stock up since Merck deal

By Stephen Heuser
Globe Staff / November 6, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

It's the classic biotechnology story. One day, you're a Kendall Square start-up with no products and an unproven idea. The next day, one of the world's largest pharmaceutical companies buys your sole competitor for more than $1 billion -- and suddenly everyone is wondering if you're the next big thing. (Full article: 892 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass